Jason Lewis

List of Publications by Citations

Source: https://exaly.com/author-pdf/988404/jason-lewis-publications-by-citations.pdf

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18,181 325 74 120 h-index g-index citations papers 6.69 20,872 7.6 348 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
325	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 169-186	19.4	532
324	Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. <i>International Journal of Radiation Biology</i> , 2006 , 82, 699-757	2.9	506
323	A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 49, 1171-82	4	365
322	89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1293-300	8.9	330
321	Copper radionuclides and radiopharmaceuticals in nuclear medicine. <i>Nuclear Medicine and Biology</i> , 1996 , 23, 957-80	2.1	321
320	In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003 , 30, 844-50	8.8	314
319	Standardized methods for the production of high specific-activity zirconium-89. <i>Nuclear Medicine and Biology</i> , 2009 , 36, 729-39	2.1	310
318	Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 55, 1233-8	4	295
317	Imaging oxygenation of human tumours. <i>European Radiology</i> , 2007 , 17, 861-72	8	270
316	PET imaging with 🖾 r: from radiochemistry to the clinic. <i>Nuclear Medicine and Biology</i> , 2013 , 40, 3-14	2.1	268
315	Cerenkov luminescence imaging of medical isotopes. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1123-30	8.9	242
314	Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. <i>Journal of Nuclear Medicine</i> , 1999 , 40, 177-83	8.9	230
313	Metal complexes as diagnostic tools. <i>Coordination Chemistry Reviews</i> , 1999 , 184, 3-66	23.2	218
312	Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. <i>Journal of Biological Inorganic Chemistry</i> , 2002 , 7, 249-59	3.7	217
311	A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1389-96	8.9	213
310	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. <i>Nature Chemical Biology</i> , 2011 , 7, 818-26	11.7	208
309	Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. <i>Science Translational Medicine</i> , 2015 , 7, 274ra17	17.5	206

(2008-2015)

308	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. <i>Science Translational Medicine</i> , 2015 , 7, 283ra51	17.5	204
307	Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). <i>Journal of Nuclear Medicine</i> , 2008 , 49, 201-5	8.9	194
306	64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , 2001 , 42, 213-21	8.9	194
305	Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. <i>Dalton Transactions</i> , 2007 , 4893-902	4.3	186
304	Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 1206-11	11.5	164
303	Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent	4	163
302	Click Chemistry and Radiochemistry: The First 10 Years. <i>Bioconjugate Chemistry</i> , 2016 , 27, 2791-2807	6.3	159
301	An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. <i>Journal of Nuclear Medicine</i> , 2008 , 49, 1177-82	8.9	148
300	The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , 2016 , 538, 397-401	50.4	148
299	A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. <i>Dalton Transactions</i> , 2011 , 40, 6168-95	4.3	144
298	Role of metalation in the topoisomerase IIIInhibition and antiproliferation activity of a series of Eheterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 2391-8	8.3	141
297	Small animal imaging. current technology and perspectives for oncological imaging. <i>European Journal of Cancer</i> , 2002 , 38, 2173-88	7.5	141
296	Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1040-1050	21.7	138
295	A novel technology for the imaging of acidic prostate tumors by positron emission tomography. <i>Cancer Research</i> , 2009 , 69, 4510-6	10.1	138
294	1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. <i>Journal of Nuclear Medicine</i> , 2008 , 49, 327-34	8.9	136
293	Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. <i>Journal of Nuclear Medicine</i> , 2001 , 42, 655-61	8.9	130
292	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 5277-85	12.9	129
291	Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. <i>Diseases of the Colon and Rectum</i> , 2008 , 51, 1641-8	3.1	126

290	Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 625-633	8.9	124
289	Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. <i>Bioconjugate Chemistry</i> , 2011 , 22, 2048-59	6.3	121
288	PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 1272-7	8.9	120
287	High purity production and potential applications of copper-60 and copper-61. <i>Nuclear Medicine and Biology</i> , 1999 , 26, 351-8	2.1	120
286	CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. <i>Genes and Development</i> , 2014 , 28, 1800-14	12.6	118
285	Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1523-1528	8.9	118
284	Alternative chelator for IZr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 4849-60	8.3	116
283	Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. <i>Annals of Nuclear Medicine</i> , 2001 , 15, 499-504	2.5	114
282	Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. <i>PLoS ONE</i> , 2010 , 5, e8859	3.7	112
281	(18)F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry. <i>Bioconjugate Chemistry</i> , 2016 , 27, 298-301	6.3	110
280	Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 2985-92	8.3	109
279	Unconventional Nuclides for Radiopharmaceuticals. <i>Molecular Imaging</i> , 2010 , 9, 7290.2010.00008	3.7	108
278	Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. <i>Bioconjugate Chemistry</i> , 2013 , 24, 1057-67	6.3	106
277	☑r-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 2093-105	8.8	103
276	Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. <i>Nuclear Medicine and Biology</i> , 2003 , 30, 725-31	2.1	102
275	89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. <i>Bioconjugate Chemistry</i> , 2011 , 22, 2383-9	6.3	100
274	Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. <i>International Journal of Nanomedicine</i> , 2010 , 5, 783-802	7.3	97
273	Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. <i>Science Signaling</i> , 2014 , 7, ra29	8.8	93

(2017-2013)

272	The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 829-32	8.9	93
271	First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1858-1864	8.9	91
270	Measurement of input functions in rodents: challenges and solutions. <i>Nuclear Medicine and Biology</i> , 2005 , 32, 679-85	2.1	88
269	Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. <i>Nuclear Medicine and Biology</i> , 2005 , 32, 623-30	2.1	86
268	Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 1341-7	8.3	86
267	First-in-Humans Imaging with Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 512-519	8.9	86
266	Basic characterization of 64Cu-ATSM as a radiotherapy agent. <i>Nuclear Medicine and Biology</i> , 2005 , 32, 21-8	2.1	85
265	Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. <i>Journal of Nuclear Medicine</i> , 1998 , 39, 1944-51	8.9	85
264	Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. <i>Cancer Research</i> , 2015 , 75, 4688-96	10.1	84
263	(64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. <i>Nuclear Medicine and Biology</i> , 2009 , 36, 277-85	2.1	84
262	Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998 , 25, 788-92	8.8	84
261	p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET. <i>Bioconjugate Chemistry</i> , 2015 , 26, 2579-91	6.3	83
260	First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 900-906	8.9	82
259	The next generation of positron emission tomography radiopharmaceuticals in oncology. <i>Seminars in Nuclear Medicine</i> , 2011 , 41, 265-82	5.4	81
258	In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake. <i>Nuclear Medicine and Biology</i> , 1999 , 26, 267-73	2.1	81
257	Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. Journal of Nuclear Medicine, 2009 , 50 Suppl 1, 106S-21S	8.9	79
256	and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019 , 9, 199-209	24.4	79
255	Multiplexed imaging for diagnosis and therapy. <i>Nature Biomedical Engineering</i> , 2017 , 1, 697-713	19	78

254	Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome. <i>PLoS ONE</i> , 2013 , 8, e64570	3.7	78
253	Annotating MYC status with 89Zr-transferrin imaging. <i>Nature Medicine</i> , 2012 , 18, 1586-91	50.5	75
252	Preparation of high specific activity (86)Y using a small biomedical cyclotron. <i>Nuclear Medicine and Biology</i> , 2005 , 32, 891-7	2.1	75
251	Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 878-884	8.9	74
250	Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 936-43	8.9	74
249	Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. <i>Nuclear Medicine and Biology</i> , 2008 , 35, 713-20	2.1	74
248	Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics. <i>Molecular Pharmaceutics</i> , 2015 , 12, 3575-87	5.6	73
247	Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. <i>Nature Communications</i> , 2016 , 7, 11838	17.4	73
246	A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1706-11	8.9	72
245	(89)Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancer. <i>Pharmaceutical Research</i> , 2013 , 30, 878-88	4.5	71
244	Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 15850-5	11.5	71
243	In vitro and in vivo evaluation of bifunctional bisthiosemicarbazone 64Cu-complexes for the positron emission tomography imaging of hypoxia. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 2985-91	8.3	69
242	Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone). <i>Journal of Nuclear Medicine</i> , 2002 , 43, 1557-69	8.9	69
241	Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals. <i>Inorganic Chemistry</i> , 2014 , 53, 1880-99	5.1	68
240	H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy. Journal of the American Chemical Society, 2013 , 135, 12707-21	16.4	68
239	(18)F-labeled-bioorthogonal liposomes for in vivo targeting. <i>Bioconjugate Chemistry</i> , 2013 , 24, 1784-9	6.3	67
238	In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 435-43	8.9	67
237	HER2-Mediated Internalization of Cytotoxic Agents in Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020 , 10, 674-687	24.4	66

236	Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. <i>Clinical Cancer Research</i> , 1999 , 5, 3608-16	12.9	66
235	Biodistribution and Dosimetry of F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 147-153	8.9	65
234	DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. <i>Bioconjugate Chemistry</i> , 2002 , 13, 721-8	6.3	65
233	Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 453-9	8.9	64
232	Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents. <i>Nuclear Medicine and Biology</i> , 2005 , 32, 147-56	2.1	64
231	Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 124-133	6.1	63
230	Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes. <i>Oral Oncology</i> , 2014 , 50, 45-51	4.4	63
229	In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models. <i>JACC: Cardiovascular Imaging</i> , 2016 , 9, 950-61	8.4	62
228	A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. <i>Journal of Urology</i> , 2014 , 191, 1439-45	2.5	62
227	Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. <i>Cancer Discovery</i> , 2012 , 2, 320-7	24.4	61
226	Pharmacokinetics, Biodistribution, and Radiation Dosimetry for Zr-Trastuzumab in Patients with Esophagogastric Cancer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 161-166	8.9	60
225	Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005 , 32, 764-70	8.8	60
224	Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018 , 4, 217-224	13.4	60
223	Radiotheranostics: a roadmap for future development. <i>Lancet Oncology, The</i> , 2020 , 21, e146-e156	21.7	59
222	Applications of pHLIP Technology for Cancer Imaging and Therapy. <i>Trends in Biotechnology</i> , 2017 , 35, 653-664	15.1	57
221	Development of a minimal saponin vaccine adjuvant based on QS-21. <i>Nature Chemistry</i> , 2014 , 6, 635-43	17.6	56
220	NuMA influences higher order chromatin organization in human mammary epithelium. <i>Molecular Biology of the Cell</i> , 2007 , 18, 348-61	3.5	56
219	Positron-emitting isotopes produced on biomedical cyclotrons. <i>Current Medicinal Chemistry</i> , 2005 , 12, 807-18	4.3	56

218	Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. <i>Journal of Nuclear Medicine</i> , 2007 , 48, 64-72	8.9	56
217	Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. <i>Molecular Pharmaceutics</i> , 2014 , 11, 3965-73	5.6	54
216	Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. <i>European Journal of Nuclear</i>	8.8	54
215	89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Clinical Nuclear Medicine, 2017 , 42, 912-917	1.7	54
214	Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1697-702	8.9	54
213	Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging. <i>Bioconjugate Chemistry</i> , 2014 , 25, 2123-8	6.3	53
212	Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. Journal of Nuclear Medicine, 2011 , 52, 1608-15	8.9	53
211	Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14). <i>Bioconjugate Chemistry</i> , 2007 , 18, 724-30	6.3	53
210	Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 53, 193-200	1.4	53
209	Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. <i>Cancer Research</i> , 2017 , 77, 3931-3941	10.1	52
208	Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation. <i>Bioconjugate Chemistry</i> , 2012 , 23, 1557-66	6.3	52
207	Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov		52
	luminescence emissions. <i>Molecular Imaging</i> , 2011 , 10, 177-86, 1-3	3.7	
206	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of F-(2S,4R)-4-Fluoroglutamine. <i>Radiology</i> , 2018 , 287, 667-675	20.5	
206	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of		51
	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of F-(2S,4R)-4-Fluoroglutamine. <i>Radiology</i> , 2018 , 287, 667-675 Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic	20.5	51
205	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of F-(2S,4R)-4-Fluoroglutamine. <i>Radiology</i> , 2018 , 287, 667-675 Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. <i>Nature Communications</i> , 2018 , 9, 5137 Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov	20.5	51
205	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of F-(2S,4R)-4-Fluoroglutamine. <i>Radiology</i> , 2018 , 287, 667-675 Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. <i>Nature Communications</i> , 2018 , 9, 5137 Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions. <i>Molecular Imaging</i> , 2011 , 10, 7290.2010.00047 H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and	20.5 17.4 3.7	51 51 50

(2010-2018)

200	Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. <i>Cancer Research</i> , 2018 , 78, 1820-1832	10.1	48	
199	Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1876-82	8.9	48	
198	Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-APPRe(Arg11)CCMSH. <i>Nuclear Medicine and Biology</i> , 2009 , 36, 345-54	2.1	48	
197	Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model. <i>International Journal of Cancer</i> , 2001 , 94, 873-7	7.5	48	
190	Pretargeting of internalizing trastuzumab and cetuximab with a F-tetrazine tracer in xenograft models. <i>EJNMMI Research</i> , 2017 , 7, 95	3.6	47	
19	Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1020-1027	8.9	47	
194	Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. <i>Nuclear Medicine and Biology</i> , 2008 , 35, 273-9	2.1	47	
193	Targeting breast tumors with pH (low) insertion peptides. <i>Molecular Pharmaceutics</i> , 2014 , 11, 2896-905	5.6	46	
192	The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies. <i>Journal of Visualized Experiments</i> , 2015 ,	1.6	46	
19:	Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate. <i>Bioconjugate Chemistry</i> , 2016 , 27, 1789-95	6.3	46	
190	H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu. Inorganic Chemistry, 2012 , 51, 12575-89	5.1	45	
189	Validation of a novel CHX-APPderivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-APPoctreotide. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 4297-304	8.3	45	
188	Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 322	- 82 8	44	
187	Unconventional nuclides for radiopharmaceuticals. <i>Molecular Imaging</i> , 2010 , 9, 1-20	3.7	44	
180	PET Imaging of Extracellular pH in Tumors with (64)Cu- and (18)F-Labeled pHLIP Peptides: A Structure-Activity Optimization Study. <i>Bioconjugate Chemistry</i> , 2016 , 27, 2014-23	6.3	43	
185	Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1350-6	8.9	43	
182	Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. <i>Nuclear Medicine and Biology</i> , 2007 , 34, 945-53	2.1	43	
183	Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia. <i>Journal of Inorganic Biochemistry</i> , 2010 , 104, 126-35	4.2	42	

182	Synthesis, in vitro and in vivo characterization of (64)Cu(I) complexes derived from hydrophilic tris(hydroxymethyl)phosphane and 1,3,5-triaza-7-phosphaadamantane ligands. <i>Journal of Biological Inorganic Chemistry</i> , 2008 , 13, 307-15	3.7	42
181	In vivo skeletal imaging of 18F-fluoride with positron emission tomography reveals damage- and time-dependent responses to fatigue loading in the rat ulna. <i>Bone</i> , 2006 , 39, 229-36	4.7	42
180	A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer. <i>Theranostics</i> , 2016 , 6, 2267-2277	12.1	42
179	Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. <i>JACC:</i> Cardiovascular Imaging, 2019 , 12, 2015-2026	8.4	42
178	Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose. <i>Cancer Research</i> , 2003 , 63, 5496-504	10.1	41
177	Clickable bifunctional radiometal chelates for peptide labeling. Chemical Communications, 2010, 46, 17	0 g. 8	40
176	Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. <i>Cancer Research</i> , 2005 , 65, 8397-405	10.1	40
175	Medical imaging and nuclear medicine: a Lancet Oncology Commission. <i>Lancet Oncology, The</i> , 2021 , 22, e136-e172	21.7	39
174	Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect. <i>Theranostics</i> , 2020 , 10, 567-584	12.1	38
173	Exploring Structural Parameters for Pretargeting Radioligand Optimization. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 8201-8217	8.3	37
172	Targeted Brain Tumor Radiotherapy Using an Auger Emitter. Clinical Cancer Research, 2020, 26, 2871-2	881 .9	37
171	Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis. <i>PET Clinics</i> , 2017 , 12, 269-288	2.2	36
170	Leveraging Bioorthogonal Click Chemistry to Improve Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 868-880	12.9	35
169	CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. <i>Radiology</i> , 2020 , 295, 606-615	20.5	35
168	Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist Lu-Satoreotide Tetraxetan. <i>Clinical Cancer Research</i> , 2019 , 25, 6939-6947	12.9	34
167	Prospective Clinical Trial of F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1037-1042	8.9	34
166	Challenges of Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2015, 21, 188-93	2.2	34
165	Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7254-9	11.5	34

164	In vivo imaging in a murine model of glioblastoma. <i>Neurosurgery</i> , 2007 , 60, 360-70; discussion 370-1	3.2	34
163	Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions. <i>Molecular Imaging</i> , 2011 , 10, 7290.2010.00047	3.7	33
162	Three-dimensional maximum a posteriori (MAP) imaging with radiopharmaceuticals labeled with three Cu radionuclides. <i>Nuclear Medicine and Biology</i> , 2006 , 33, 217-26	2.1	33
161	Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000 , 27, 638-46	8.8	33
160	What a difference a carbon makes: Höctapa vs Hü3octapa, ligands for In-111 and Lu-177 radiochemistry. <i>Inorganic Chemistry</i> , 2014 , 53, 10412-31	5.1	32
159	Imaging tumor burden in the brain with 89Zr-transferrin. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 90-5	8.9	31
158	Improved synthesis of 2Pdeoxy-2P[18F]-fluoro-1-beta-D-arabinofuranosyl-5-iodouracil ([18F]-FIAU). <i>Nuclear Medicine and Biology</i> , 2010 , 37, 439-42	2.1	30
157	Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers. <i>Bioconjugate Chemistry</i> , 2018 , 29, 538-545	6.3	28
156	PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1225-1233	8.9	28
155	Evaluation of hypoxia with copper-labeled diacetyl-bis(N-methylthiosemicarbazone). <i>Seminars in Nuclear Medicine</i> , 2015 , 45, 177-85	5.4	28
154	Molecular imaging: the application of small animal positron emission tomography. <i>Journal of Cellular Biochemistry</i> , 2002 , 39, 110-5	4.7	28
153	Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma. <i>Molecular Pharmaceutics</i> , 2018 , 15, 1729-1734	5.6	27
152	Biodistribution and radiation dose estimates for Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 677-685	8.8	27
151	The inverse electron-demand Diels-Alder reaction as a new methodology for the synthesis of Ac-labelled radioimmunoconjugates. <i>Chemical Communications</i> , 2018 , 54, 2599-2602	5.8	26
150	A phase II study of radioimmunotherapy with intraventricular I-3F8 for medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e26754	3	26
149	Noninvasive Zr-Transferrin PET Shows Improved Tumor Targeting Compared with F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 51-57	7 ^{8.9}	26
148	Copper(I) bis(diphosphine) complexes as a basis for radiopharmaceuticals for positron emission tomography and targeted radiotherapy. <i>Chemical Communications</i> , 1996 , 1093	5.8	26
147	Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 7014-702	3 ^{12.9}	25

146	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer Cell, 2019, 36, 559-573.e7	24.3	25
145	Copper-64-pyruvaldehyde-bis(N(4)-methylthiosemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy response with microPET and magnetic resonance imaging. <i>Cancer Research</i> , 2002 , 62, 445-9	10.1	25
144	Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1386-1394	8.9	24
143	Noninvasive Measurement of mTORC1 Signaling with Zr-Transferrin. <i>Clinical Cancer Research</i> , 2017 , 23, 3045-3052	12.9	24
142	Imaging of human epidermal growth factor receptors for patient selection and response monitoring - From PET imaging and beyond. <i>Cancer Letters</i> , 2018 , 419, 139-151	9.9	24
141	Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review. <i>Journal of Thrombosis and Thrombolysis</i> , 2007 , 23, 135-45	5.1	24
140	A tat fusion protein-based tumor vaccine for breast cancer. <i>Annals of Surgical Oncology</i> , 2005 , 12, 517-2	253.1	24
139	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. <i>Nature Communications</i> , 2018 , 9, 1629	17.4	23
138	Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E7441-E7449	11.5	22
137	An anatomical study of tibial metaphyseal/diaphyseal mismatch during revision total knee arthroplasty. <i>Journal of Arthroplasty</i> , 2007 , 22, 241-4	4.4	22
136	Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2000 , 15, 593-604	3.9	22
135	The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 263S-272S	8.9	22
134	Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with Zr-5B1. <i>Molecular Pharmaceutics</i> , 2017 , 14, 908-915	5.6	21
133	A comparative evaluation of the chelators H4octapa and CHX-A?-DTPA with the therapeutic radiometal (90)Y. <i>Nuclear Medicine and Biology</i> , 2016 , 43, 566-576	2.1	21
132	Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis. <i>ChemistryOpen</i> , 2014 , 3, 48-53	2.3	21
131	Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. <i>ACS Chemical Biology</i> , 2017 , 12, 2085-2096	4.9	20
130	Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 2045-9	8.9	20
129	Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1811-1816	8.9	20

128	64Cu-azabicyclo[3.2.2]nonane thiosemicarbazone complexes: radiopharmaceuticals for PET of topoisomerase II expression in tumors. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 2034-41	8.9	20
127	Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis. Journal of Nuclear Medicine, 2016 , 57, 771-6	8.9	19
126	Effect of ligand and solvent on chloride ion coordination in anti-tumour copper(I) diphosphine complexes: Synthesis of [Cu(dppe)2]Cl and analogous complexes (dppe = 1,2-bis(diphenylphosphino)ethane). <i>Polyhedron</i> , 1998 , 17, 513-517	2.7	19
125	Harnessing Cu/Cu for a theranostic approach to pretargeted radioimmunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 28316-28327	11.5	19
124	B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4283-4291	2.2	19
123	Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model. <i>Molecular Imaging and Biology</i> , 2018 , 20, 808-815	3.8	18
122	Diphosphine bifunctional chelators for low-valent metal ions. Crystalstructures of the copper(I) complexes [CuClL12]and [CuL12][PF6][L1 = 2,3-bis(diphenylphosphino)maleicanhydride]. <i>Journal of the Chemical Society Dalton Transactions</i> , 1997 , 855-862		18
121	Utilization of metabolic, transport and receptor-mediated processes to deliver agents for cancer diagnosis. <i>Advanced Drug Delivery Reviews</i> , 1999 , 37, 189-211	18.5	18
120	Rhenium complex of a triply deprotonated chelated thiosemicarbazide and its conversion to a nitride complex via a hydrazide intermediate. Crystal structure of [ReCl2(NH)(NHNH2)(PPh3)2]. Journal of the Chemical Society Dalton Transactions, 1995, 1357		18
119	The Impact of Positron Range on PET Resolution, Evaluated with Phantoms and PHITS Monte Carlo Simulations for Conventional and Non-conventional Radionuclides. <i>Molecular Imaging and Biology</i> , 2020 , 22, 73-84	3.8	18
118	Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 1569-1578	8.9	17
117	A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals. <i>Nuclear Medicine and Biology</i> , 2019 , 71, 32-38	2.1	16
116	Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018 , 61, 611-635	1.9	16
115	Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies. <i>Nuclear Medicine and Biology</i> , 2008 , 35, 655-63	2.1	16
114	Radiopharmaceuticals for targeted radiotherapy of cancer. <i>Expert Opinion on Therapeutic Patents</i> , 2000 , 10, 1057-1069	6.8	16
113	Radiometal-labeled somatostatin analogs for applications in cancer imaging and therapy. <i>Methods in Molecular Biology</i> , 2007 , 386, 227-40	1.4	16
112	Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016 , 59, 129-32	1.9	16
111	PET imaging of hypoxia. <i>The Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)</i> , 2001 , 45, 183-8		16

110	Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma. <i>Cancer Research</i> , 2017 , 77, 3113-3120	10.1	15
109	Current status and future challenges for molecular imaging. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2017 , 375,	3	15
108	The Influence of Glycans-Specific Bioconjugation on the FcRI Binding and Performance of Zr-DFO-Pertuzumab. <i>Theranostics</i> , 2020 , 10, 1746-1757	12.1	15
107	Safety and Feasibility of PARP1/2 Imaging with F-PARPi in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3110-3116	12.9	15
106	Imaging EGFR and HER3 through Zr-labeled MEHD7945A (Duligotuzumab). <i>Scientific Reports</i> , 2018 , 8, 9043	4.9	15
105	Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. <i>Science Translational Medicine</i> , 2016 , 8, 367ra167	17.5	15
104	Head-to-Head Evaluation of F-FES and F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. Journal of Nuclear Medicine, 2021 , 62, 326-331	8.9	15
103	Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer. <i>PET Clinics</i> , 2018 , 13, 423-435	2.2	15
102	The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. <i>Nuclear Medicine and Biology</i> , 2011 , 38, 683-96	2.1	14
101	The preparation of rhenium(V) oxo and imido complexes with Et2NCSNHCOPh and Et2NCSBC(NH)Ph. The x-ray crystal structure of [ReOCl(PhCONCSNEt2)2]. <i>Polyhedron</i> , 1993 , 12, 221-22.	5 ^{2.7}	14
100	ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors. <i>Theranostics</i> , 2020 , 10, 151-165	12.1	14
99	An Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 433-436	8.9	14
98	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2642-2651	8.8	14
97	Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy. <i>Molecular Pharmaceutics</i> , 2019 , 16, 2259-2263	5.6	13
96	Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-Pertuzumab PET/CT. <i>Radiology</i> , 2020 , 296, 370-378	20.5	13
95	Reproducibility and Repeatability of Semiquantitative F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1516-1523	8.9	13
94	Biodistribution and Dosimetry of Intraventricularly Administered I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 1794-1801	8.9	13
93	Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy. <i>Journal of Neuro-Oncology</i> , 2015 , 123, 245-9	4.8	13

(2012-2009)

92	Bromination from the macroscopic level to the tracer radiochemical level: (76)Br radiolabeling of aromatic compounds via electrophilic substitution. <i>Bioconjugate Chemistry</i> , 2009 , 20, 808-16	6.3	13
91	Synthesis and characterization of the copper(II) complexes of new N2S2-donor macrocyclic ligands: synthesis and in vivo evaluation of the (64)Cu complexes. <i>Dalton Transactions</i> , 2009 , 177-84	4.3	13
90	Production of non-standard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides. <i>Ernst Schering Research Foundation Workshop</i> , 2007 , 159-81		13
89	Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. <i>ChemMedChem</i> , 2021 , 16, 2909-2941	3.7	13
88	Tim-4 cavity-resident macrophages impair anti-tumor CD8 Ttell immunity. Cancer Cell, 2021, 39, 973-98	8& q 93	13
87	Molecular Imaging of Ovarian Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 827-33	8.9	13
86	Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 881-891	12.9	13
85	Acid specific dark quencher QC1 pHLIP for multi-spectral optoacoustic diagnoses of breast cancer. <i>Scientific Reports</i> , 2019 , 9, 8550	4.9	12
84	Multimodal Positron Emission Tomography Imaging to Quantify Uptake of Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. <i>Bioconjugate Chemistry</i> , 2020 , 31, 360-368	6.3	12
83	Trastuzumab gold-conjugates: synthetic approach and in vitro evaluation of anticancer activities in breast cancer cell lines. <i>Chemical Communications</i> , 2019 , 55, 1394-1397	5.8	11
82	Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue. <i>Nuclear Medicine and Biology</i> , 2020 , 84-85, 63-72	2.1	11
81	Applying IZr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. <i>Molecular Pharmaceutics</i> , 2016 , 13, 683-8	5.6	11
80	Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice. <i>Vaccine</i> , 2003 , 21, 2667-77	4.1	11
79	HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer. <i>Molecular Pharmaceutics</i> , 2020 , 17, 327-337	5.6	11
78	Oncology-Inspired Treatment Options for COVID-19. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1720-1723	8.9	11
77	iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. <i>Cancer Research</i> , 2020 , 80, 1681-1692	10.1	11
76	Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging. <i>Molecular Imaging and Biology</i> , 2012 , 14, 25-31	3.8	10
75	An improved strategy for the synthesis of [IE]-labeled arabinofuranosyl nucleosides. <i>Nuclear Medicine and Biology</i> , 2012 , 39, 1182-8	2.1	10

74	A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 166-176	12.9	10
73	PARaDIM: A PHITS-Based Monte Carlo Tool for Internal Dosimetry with Tetrahedral Mesh Computational Phantoms. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 1802-1811	8.9	9
72	Inhibiting cancer metabolism by aromatic carbohydrate amphiphiles that act as antagonists of the glucose transporter GLUT1. <i>Chemical Science</i> , 2020 , 11, 3737-3744	9.4	9
71	Synthesis and evaluation of an (18)F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas. <i>Nuclear Medicine and Biology</i> , 2016 , 43, 606-11	2.1	9
70	Influence of free fatty acids on glucose uptake in prostate cancer cells. <i>Nuclear Medicine and Biology</i> , 2014 , 41, 254-8	2.1	9
69	Sandmeyer reaction repurposed for the site-selective, non-oxidizing radioiodination of fully-deprotected peptides: studies on the endogenous opioid peptide Eheoendorphin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013 , 23, 4347-50	2.9	9
68	Copper-64 Radiopharmaceuticals for Oncologic Imaging. PET Clinics, 2009, 4, 49-67	2.2	9
67	Acute Statin Treatment Improves Antibody Accumulation in EGFR- and PSMA-Expressing Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 6215-6229	12.9	9
66	A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89. <i>Inorganic Chemistry</i> , 2020 , 59, 11715-11727	5.1	9
65	Fully-automated synthesis of 16E(18)F-fluoro-5Edihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer. <i>Applied Radiation and Isotopes</i> , 2015 , 103, 9-14	1.7	8
64	First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 5178-5187	12.9	8
63	Long-Half-Life Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 399-402	8.9	8
62	Fully automated synthesis of [(18) F]fluoro-dihydrotestosterone ([(18) F]FDHT) using the FlexLab module. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016 , 59, 424-8	1.9	8
61	Synthesis and evaluation of (18)F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression. <i>European Journal of Medicinal Chemistry</i> , 2014 , 86, 769-81	6.8	8
60	Multimodality labeling strategies for the investigation of nanocrystalline cellulose biodistribution in a mouse model of breast cancer. <i>Nuclear Medicine and Biology</i> , 2020 , 80-81, 1-12	2.1	8
59	Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [Cu]Cu-NOTA-anti-CD8 PET. <i>Clinical Cancer Research</i> , 2021 , 27, 1958-1966	12.9	8
58	Ex vivo sentinel lymph node mapping in laparoscopic resection of colon cancer. <i>Colorectal Disease</i> , 2011 , 13, 1249-55	2.1	7
57	Comparison of Methods for Surface Modification of Barium Titanate Nanoparticles for Aqueous Dispersibility: Toward Biomedical Utilization of Perovskite Oxides. <i>ACS Applied Materials & Interfaces</i> , 2020 , 12, 51135-51147	9.5	7

(2020-2020)

56	Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following 🛭 and Eparticle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. <i>Theranostics</i> , 2020 , 10, 5802-5814	12.1	6
55	A Systematic Evaluation of Antibody Modification and Zr-Radiolabeling for Optimized Immuno-PET. <i>Bioconjugate Chemistry</i> , 2021 , 32, 1177-1191	6.3	6
54	Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO. <i>Organic and Biomolecular Chemistry</i> , 2019 , 17, 6866-6871	3.9	6
53	Harnessing the bioorthogonal inverse electron demand Diels-Alder cycloaddition for pretargeted PET imaging. <i>Journal of Visualized Experiments</i> , 2015 , e52335	1.6	6
52	Functionalised copper-64 complexes as precursors of potential PET imaging agents for neurodegenerative disorders. <i>New Journal of Chemistry</i> , 2009 , 33, 1845	3.6	6
51	Fluorescence labeling of a Na1.7-targeted peptide for near-infrared nerve visualization. <i>EJNMMI Research</i> , 2020 , 10, 49	3.6	6
50	Leveraging PET to image folate receptor [therapy of an antibody-drug conjugate. <i>EJNMMI Research</i> , 2018 , 8, 87	3.6	6
49	Assessment of Simplified Methods for Quantification of F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 1221-1227	8.9	5
48	Manipulating the In Vivo Behaviour of Ga with Tris(Hydroxypyridinone) Chelators: Pretargeting and Blood Clearance. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
47	Demarcation of Sepsis-Induced Peripheral and Central Acidosis with pH (Low) Insertion Cycle Peptide. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1361-1368	8.9	5
46	pHLIP ICG for delineation of tumors and blood flow during fluorescence-guided surgery. <i>Scientific Reports</i> , 2020 , 10, 18356	4.9	5
45	ImmunoPET Imaging of Pancreatic Tumors with Zr-Labeled Gold Nanoparticle-Antibody Conjugates. <i>Molecular Imaging and Biology</i> , 2021 , 23, 84-94	3.8	5
44	Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. <i>Nature Communications</i> , 2021 , 12, 4669	17.4	5
43	ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 2026-2034	6.1	5
42	Comparison of Ga-DOTA-JR11 PET/CT with dosimetric Lu-satoreotide tetraxetan (Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 3047-3057	8.8	4
41	pH-Responsive Polymers for Improving the Signal-to-Noise Ratio of Hypoxia PET Imaging with [F]Fluoromisonidazole. <i>Macromolecular Rapid Communications</i> , 2020 , 41, e2000061	4.8	4
40	Polyazamacrocycle Ligands Facilitate Zr Radiochemistry and Yield Zr Complexes with Remarkable Stability. <i>Inorganic Chemistry</i> , 2020 , 59, 17473-17487	5.1	4
39	First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1580-1587	8.9	3

38	A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2020 , 17, 3140-3147	5.6	3
37	PET/CT Imaging with an F-Labeled Galactodendritic Unit in a Galectin-1-Overexpressing Orthotopic Bladder Cancer Model. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1369-1375	8.9	3
36	Antilipolytic drug boosts glucose metabolism in prostate cancer. <i>Nuclear Medicine and Biology</i> , 2013 , 40, 524-8	2.1	3
35	Antibody-Targeted Imaging of Gastric Cancer. <i>Molecules</i> , 2020 , 25,	4.8	3
34	Aromatic carbohydrate amphiphile disrupts cancer spheroids and prevents relapse. <i>Nanoscale</i> , 2020 , 12, 19088-19092	7.7	3
33	Applications of nuclear-based imaging in gene and cell therapy: probe considerations. <i>Molecular Therapy - Oncolytics</i> , 2021 , 20, 447-458	6.4	3
32	Radiopharmaceuticals for Imaging in Oncology with Special Emphasis on Positron-Emitting Agents 2013 , 35-78		2
31	Copper-64/61 and iodine-125-labeled dota-DTYR1-octreotate: A new somatostatin analog for labeling with metals and halogens. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001 , 44, S948-S950	1.9	2
30	Predicting CAR-T cell Immunotherapy Success through ImmunoPET. <i>Clinical Cancer Research</i> , 2021 , 27, 911-912	12.9	2
29	PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer		2
29	PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer Targeted brain tumor radiotherapy using an Auger emitter		2
		2681	2
28	Targeted brain tumor radiotherapy using an Auger emitter	2 58 1 1	2
28	Targeted brain tumor radiotherapy using an Auger emitter Leveraging synthetic chlorins for bio-imaging applications. <i>Chemical Communications</i> , 2020 , 56, 12608-1 Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted	8.9	2
28 27 26	Targeted brain tumor radiotherapy using an Auger emitter Leveraging synthetic chlorins for bio-imaging applications. <i>Chemical Communications</i> , 2020 , 56, 12608-1 Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 366-371 Imaging of Cancer Esecretase Activity Using an Inhibitor-Based PET Probe. <i>Clinical Cancer Research</i> ,	8.9	2 2
28 27 26 25	Targeted brain tumor radiotherapy using an Auger emitter Leveraging synthetic chlorins for bio-imaging applications. <i>Chemical Communications</i> , 2020 , 56, 12608-1 Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 366-371 Imaging of Cancer Esecretase Activity Using an Inhibitor-Based PET Probe. <i>Clinical Cancer Research</i> , 2021 , 27, 6145-6155	8.9	2 2 2
28 27 26 25 24	Targeted brain tumor radiotherapy using an Auger emitter Leveraging synthetic chlorins for bio-imaging applications. <i>Chemical Communications</i> , 2020 , 56, 12608-1 Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 366-371 Imaging of Cancer Esecretase Activity Using an Inhibitor-Based PET Probe. <i>Clinical Cancer Research</i> , 2021 , 27, 6145-6155 Molecular Imaging Companion Diagnostics 2019 , 201-228 Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer	8.9	2 2 2 2

(2021-2021)

20	Imaging Early-Stage Metastases Using an F-Labeled VEGFR-1-Specific Single Chain VEGF Mutant. <i>Molecular Imaging and Biology</i> , 2021 , 23, 340-349	3.8	1
19	Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer <i>Nature Communications</i> , 2022 , 13, 2526	17.4	1
18	Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer exhibits antitumor efficacy with low toxicity <i>Clinical Cancer Research</i> , 2022 ,	12.9	0
17	"Friction by Definition": Conflict at Patient Handover Between Emergency and Internal Medicine Physicians at an Academic Medical Center. <i>Western Journal of Emergency Medicine</i> , 2021 , 22, 1227-1239	3.3	O
16	3D-Printable Platform for High-Throughput Small-Animal Imaging. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1691-1692	8.9	О
15	Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1384-1390	8.9	O
14	Technical Note: Patient-morphed mesh-type phantoms to support personalized nuclear medicine dosimetry - a proof of concept study. <i>Medical Physics</i> , 2021 , 48, 2018-2026	4.4	О
13	Synthesis and Comparative Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. <i>Bioconjugate Chemistry</i> , 2021 , 32, 1255-1262	6.3	O
12	Bimodal Imaging of Mouse Peripheral Nerves with Chlorin Tracers. <i>Molecular Pharmaceutics</i> , 2021 , 18, 940-951	5.6	0
11	Emerging Radiopharmaceuticals in Clinical Oncology 2016 , 1-43		
10	Radiolabeled Antibodies for Tumor Imaging and Therapy 2005 , 685-714		
9	64Cu-PTSM as an inhibitor of tumor recurrence. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001 , 44, S87-S89	1.9	
8	Radiopharmaceuticals in Oncology 2020 , 535-570		
7	Novel Positron Emitting Radiopharmaceuticals 2016 , 1-43		
6	Novel Positron-Emitting Radiopharmaceuticals 2017 , 129-171		
5	SU-GG-J-03: 3D Pathology Validation for Head-And-Neck Tumor Segmentation in PET/CT/MRI Images. <i>Medical Physics</i> , 2008 , 35, 2679-2679	4.4	
4	Reply: Potential Use of Radiolabeled Antibodies for Imaging and Treatment of COVID-19. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1020-1021	8.9	
3	Antibody-Based Molecular Imaging 2021 , 547-562		

- Novel Tracers and Radionuclides in PET Imaging. *Radiologic Clinics of North America*, **2021**, 59, 887-918 2.3
- Novel Positron-Emitting Radiopharmaceuticals **2022**, 1-48